# Cutaneous lymphoproliferative disorders research

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/cutaneous-lymphoproliferative-disorders-research/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the classification, staging, treatment, and prognosis of cutaneous lymphomas, with a specific emphasis on mycosis fungoides and Sézary syndrome. It includes discussions on the WHO-EORTC classification, survival outcomes, prognostic factors, and various treatment options such as bexarotene and denileukin diftitox. The cluster also addresses the incidence patterns, genomic landscape, and molecular profiling of cutaneous T-cell lymphomas. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11811 |
| Works | 102 |

## Topic papers all

Showing 15 of 102.

- [T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial](https://scholariq.org/papers/t-cells-expressing-cd19-chimeric-antigen-receptors-for-acute-lymphoblastic/)
- [Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.](https://scholariq.org/papers/rituximab-chimeric-anti-cd20-monoclonal-antibody-therapy-for-relapsed-indolent/)
- [Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/anti-bcma-car-t-cell-therapy-bb2121-in-relapsed-or-refractory-multiple-myeloma/)
- [Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma](https://scholariq.org/papers/adoptive-cell-transfer-therapy-following-non-myeloablative-but-lymphodepleting/)
- [Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor](https://scholariq.org/papers/chemotherapy-refractory-diffuse-large-b-cell-lymphoma-and-indolent-b-cell/)
- [Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)](https://scholariq.org/papers/revisions-to-the-staging-and-classification-of-mycosis-fungoides-and-sezary/)
- [Obinutuzumab for the First-Line Treatment of Follicular Lymphoma](https://scholariq.org/papers/obinutuzumab-for-the-first-line-treatment-of-follicular-lymphoma/)
- [Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma](https://scholariq.org/papers/polatuzumab-vedotin-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/)
- [Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project](https://scholariq.org/papers/follicular-lymphoma-international-prognostic-index-2-a-new-prognostic-index-for/)
- [Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial](https://scholariq.org/papers/brentuximab-vedotin-with-chemotherapy-for-cd30-positive-peripheral-t-cell/)
- [KAPOSI'S SARCOMA IN HOMOSEXUAL MEN—A REPORT OF EIGHT CASES](https://scholariq.org/papers/kaposi-s-sarcoma-in-homosexual-men-a-report-of-eight-cases/)
- [Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer](https://scholariq.org/papers/clinical-end-points-and-response-criteria-in-mycosis-fungoides-and-sezary/)
- [Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial](https://scholariq.org/papers/mogamulizumab-versus-vorinostat-in-previously-treated-cutaneous-t-cell-lymphoma/)
- [Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma](https://scholariq.org/papers/phase-iii-study-to-evaluate-temsirolimus-compared-with-investigator-s-choice/)
- [Guidelines of care for the management of cutaneous squamous cell carcinoma](https://scholariq.org/papers/guidelines-of-care-for-the-management-of-cutaneous-squamous-cell-carcinoma/)

## Topic primary papers

Showing 15 of 31.

- [Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)](https://scholariq.org/papers/revisions-to-the-staging-and-classification-of-mycosis-fungoides-and-sezary/)
- [Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer](https://scholariq.org/papers/clinical-end-points-and-response-criteria-in-mycosis-fungoides-and-sezary/)
- [Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial](https://scholariq.org/papers/mogamulizumab-versus-vorinostat-in-previously-treated-cutaneous-t-cell-lymphoma/)
- [Defining early mycosis fungoides](https://scholariq.org/papers/defining-early-mycosis-fungoides/)
- [TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)](https://scholariq.org/papers/tnm-classification-system-for-primary-cutaneous-lymphomas-other-than-mycosis/)
- [European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas](https://scholariq.org/papers/european-organization-for-research-and-treatment-of-cancer-and-international/)
- [European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017](https://scholariq.org/papers/european-organisation-for-research-and-treatment-of-cancer-consensus/)
- [Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model](https://scholariq.org/papers/cutaneous-lymphoma-international-consortium-study-of-outcome-in-advanced-stages/)
- [EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*](https://scholariq.org/papers/eortc-iscl-and-usclc-consensus-recommendations-for-the-treatment-of-primary/)
- [EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome](https://scholariq.org/papers/eortc-consensus-recommendations-for-the-treatment-of-mycosis-fungoides-sezary/)
- [The Pathogenesis of Mycosis Fungoides](https://scholariq.org/papers/the-pathogenesis-of-mycosis-fungoides/)
- [Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma](https://scholariq.org/papers/multicenter-phase-ii-study-of-mogamulizumab-kw-0761-a-defucosylated-anti-cc/)
- [Subcutaneous Panniculitis-like T-Cell Lymphoma](https://scholariq.org/papers/subcutaneous-panniculitis-like-t-cell-lymphoma/)
- [WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects](https://scholariq.org/papers/who-eortc-classification-of-cutaneous-lymphomas-2005-histological-and-molecular/)
- [Modern Radiation Therapy for Primary Cutaneous Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group](https://scholariq.org/papers/modern-radiation-therapy-for-primary-cutaneous-lymphomas-field-and-dose/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.